HCPCS Level II J3590: Unclassified Biologics
HCPCS Level II code J3590 designates unclassified biologics and is applied when a biologic product lacks a specific HCPCS Level II code. This code matters nationally because biologic therapies drive a growing share of specialty drug spend, and use of an unclassified code can affect claims processing, coverage determinations, and billing transparency. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise briefing on what J3590 represents, its clinical and service context, and the operational implications for outpatient and facility-based biologic administration. The publication summarizes common modifier usage patterns and payer considerations where available, describes the typical sites of service for biologic administration, and outlines what information is missing from the input. It also provides benchmarks and policy-focused observations relevant to coding, claims adjudication, and payer coverage practice nationally.
This summary is intended to help billing staff, revenue cycle leaders, and policy analysts understand the role of J3590 in billing workflows and payer interactions when a specific HCPCS Level II code for a biologic product is not assigned.
Sign up for hcpcs J3590 policy alerts
Get alerted when payer policies referencing J3590 are released or updated.
Billing Code Overview
HCPCS Level II code J3590 denotes unclassified biologics. This code is used for biologic drugs or biological products that do not have a specific HCPCS Level II code assigned. The service type is biologic drug administration or supply, and the typical site of service is outpatient infusion/clinic or facility-based administration where biologic agents are administered or provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a rare or newly available biologic therapy that lacks a specific HCPCS code. The patient has a documented diagnosis such as refractory autoimmune disease, severe dermatologic or ophthalmologic inflammatory disorder, or a rare hematologic condition for which an unclassified biologic is prescribed. The ordering specialist (rheumatologist, dermatology, ophthalmology, or hematology/oncology) documents the medical necessity, prior therapy failure, and measurable treatment goals in the chart. Pharmacy or infusion clinic staff receive the medication from the physician’s office or specialty pharmacy, confirm dosing and lot numbers, and prepare the biologic under sterile conditions. The biologic is administered via intravenous infusion or subcutaneous injection in an outpatient infusion center, physician office, or hospital outpatient department. Clinical workflow steps include: pre-administration verification (allergies, baseline labs), consent and time-based documentation, administration (including start/stop times and route), lot and manufacturer documentation, and post-administration monitoring for adverse reactions. Billing uses J3590 for the product; appropriate modifiers are appended to indicate unusual circumstances (e.g., billed as single-source unclassified biologic, partial administration, or patient status). Payers involved commonly include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage determination and prior authorization processing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When partial vial waste is discarded and payer requires reporting of discarded biologic amount |
JZ | No drug wasted/entire drug administered | When the entire dispensed biologic is administered to the patient |
59 | Distinct procedural service | To indicate a separate and distinct service when another procedure on the same day is unrelated |
52 | Reduced service | When the biologic dose or service is intentionally reduced from standard |
53 | Discontinued procedure | When administration is started but discontinued due to patient reaction or intolerance |
62 | Two surgeons | Rarely used if two physicians of different specialties share surgical responsibilities related to biologic delivery procedures |
GA | Waiver of liability statement on file | When a voluntary payer-required ABN or similar waiver is on file for an item not covered |
GZ | Item/service expected to be denied as not reasonable/necessary | When the provider expects denial for medical necessity and wants to indicate that on claim |
Q6 | Service furnished under a prescription or order | To indicate the biologic was furnished under a prescription (commonly used for drugs billed by providers) |
JW | (duplicate avoided) | (see above) |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RI0000X | Internal Medicine (Rheumatology) | Rheumatologists commonly prescribe biologic therapies for autoimmune diseases |
207N00000X | Dermatology | Dermatologists prescribe biologics for severe psoriasis and dermatologic autoimmune disorders |
207RH0000X | Hematology & Oncology | Hematology/oncology providers may use biologics for hematologic disorders or supportive care |
363LF0000X | Clinical Laboratory | Clinical pharmacists and infusion clinics manage biologic preparation and monitoring |
2084P0800X | Allergy & Immunology | Allergy/immunology specialists manage biologics for immune-mediated conditions |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M05.79 | Rheumatoid arthritis with rheumatoid factor, multiple sites without organ or systems involvement | Common indication for biologic therapy when disease is refractory to DMARDs |
L40.0 | Psoriasis vulgaris | Severe plaque psoriasis cases may be treated with biologic agents when topical/systemic therapy fails |
H20.9 | Iridocyclitis, unspecified | Some ocular inflammatory conditions are managed with biologic immunomodulators |
D69.59 | Other primary thrombocytopenia | Certain hematologic immune-mediated disorders may be treated with biologic agents |
M32.10 | Systemic lupus erythematosus, organ or system involvement unspecified | Biologic agents are used for refractory systemic autoimmune disease in select cases |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96365 | Intravenous infusion, initial, up to 1 hour | Commonly billed for the initial infusion session when J3590 biologic is administered IV |
96366 | Intravenous infusion, each additional hour | Used when an infusion extends beyond the initial hour for the biologic therapy |
96372 | Therapeutic, prophylactic, or diagnostic injection (SC/IM) | Used if the biologic is delivered by subcutaneous injection in office setting |
36415 | Collection of venous blood by venipuncture | Performed for baseline and monitoring labs before and during biologic therapy |
99070 | Supplies and materials (non-covered) | Applied when special single-use supplies specific to biologic administration are billed separately |
96377 | Infusion management for attachment of external pump | Used when infusion requires external infusion pump management as part of biologic therapy |